Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges

The recent outbreak of Coronavirus disease (COVID-19), first in Eastern Asia and then essentially across the world has been declared a pandemic by the WHO. COVID-19 is caused by a novel virus SARS-CoV2 (2019-nCoV), against which there is currently no vaccine available; and current antiviral therapie...

Full description

Autores:

Tipo de recurso:

Article of investigation

Fecha de publicación:

2020

Institución:

Universidad de Bogotá Jorge Tadeo Lozano

Repositorio:

Expeditio: repositorio UTadeo

Idioma:

eng

OAI Identifier:

oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12452

Acceso en línea:

https://doi.org/10.1016/j.lfs.2020.118275
http://hdl.handle.net/20.500.12010/12452

Palabra clave:

Covid-19
Drug repurposing
FDA approved drugs
SARS-CoV2
Localized delivery
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus

Rights

License

Acceso restringido